Safety and Efficacy of Factor XIa Inhibition with Milvexian for Secondary Stroke Prevention (AXIOMATIC-SSP): a Phase 2, International, Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Trial Mukul Sharma , Carlos A. Molina , Kazunori Toyoda , Daniel Bereczki , Shrikant Bangdiwala , Scott E. Kasner , Helmi L. Lutsep , Georgios Tsivgoulis , George Ntaios , Anna Czlonkowska , Ashfaq Shuaib , Pierre Amarenco , Matthias Endres , Byung-Woo Yoon , David Tanne , Danilo Toni , Laetitia Yperzeele , Paul von Weitzel-Mudersbach , Gisele Sampaio Silva , Alvaro Avezum , Jesse Dawson , Daniel Strbian , Turgut Tatlisumak , Jens Eckstein , Sebastian F. Ameriso , Joerg R. Weber , Else Charlotte Sandset , Nana Goar Pogosova , Pablo M. Lavados , Antonio Arauz , David Gailani , Hans-Christoph Diener , Richard A. Bernstein , Charlotte Cordonnier , Anja Kahl , Grigor Abelian , Mark Donovan , Chahin Pachai , Danshi Li , Graeme J. Hankey LANCET NEUROLOGY（2024）
Key words
Factor XI Antisense Oligonucleotide
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
